ERBB2 and gastric cancer: New drugs and treatment strategies, such as adjuvant chemotherapy with S-1, oral fluoropyrimidine in patients with advanced gastric cancer after surgical intervention, and targeted therapy with trastuzumab in HER2-positive advanced gastric cancer patients, have shown survival benefits (25, 26).